298 related articles for article (PubMed ID: 8665515)
1. Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells.
Love-Schimenti CD; Gibson DF; Ratnam AV; Bikle DD
Cancer Res; 1996 Jun; 56(12):2789-94. PubMed ID: 8665515
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen.
Vink-van Wijngaarden T; Pols HA; Buurman CJ; van den Bemd GJ; Dorssers LC; Birkenhäger JC; van Leeuwen JP
Cancer Res; 1994 Nov; 54(21):5711-7. PubMed ID: 7923220
[TBL] [Abstract][Full Text] [Related]
3. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
4. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells.
James SY; Mackay AG; Binderup L; Colston KW
J Endocrinol; 1994 Jun; 141(3):555-63. PubMed ID: 8071654
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
[TBL] [Abstract][Full Text] [Related]
6. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia.
Abe J; Nakano T; Nishii Y; Matsumoto T; Ogata E; Ikeda K
Endocrinology; 1991 Aug; 129(2):832-7. PubMed ID: 1855478
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a vitamin D3-resistant MCF-7 cell line.
Narvaez CJ; Vanweelden K; Byrne I; Welsh J
Endocrinology; 1996 Feb; 137(2):400-9. PubMed ID: 8593782
[TBL] [Abstract][Full Text] [Related]
8. Dissociation of vitamin D3 and anti-estrogen mediated growth regulation in MCF-7 breast cancer cells.
Nolan E; Donepudi M; VanWeelden K; Flanagan L; Welsh J
Mol Cell Biochem; 1998 Nov; 188(1-2):13-20. PubMed ID: 9823006
[TBL] [Abstract][Full Text] [Related]
9. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines.
Elstner E; Linker-Israeli M; Said J; Umiel T; de Vos S; Shintaku IP; Heber D; Binderup L; Uskokovic M; Koeffler HP
Cancer Res; 1995 Jul; 55(13):2822-30. PubMed ID: 7796409
[TBL] [Abstract][Full Text] [Related]
10. Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment.
Christensen GL; Jepsen JS; Fog CK; Christensen IJ; Lykkesfeldt AE
Breast Cancer Res Treat; 2004 May; 85(1):53-63. PubMed ID: 15039597
[TBL] [Abstract][Full Text] [Related]
11. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
12. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
13. A-ring analogues of 1, 25-(OH)2D3 with low affinity for the vitamin D receptor modulate chondrocytes via membrane effects that are dependent on cell maturation.
Greising DM; Schwartz Z; Posner GH; Sylvia VL; Dean DD; Boyan BD
J Cell Physiol; 1997 Jun; 171(3):357-67. PubMed ID: 9180905
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089.
Vink-van Wijngaarden T; Pols HA; Buurman CJ; Birkenhäger JC; van Leeuwen JP
Eur J Cancer; 1996 May; 32A(5):842-8. PubMed ID: 9081364
[TBL] [Abstract][Full Text] [Related]
15. Antiestrogens inhibit in vitro bone resorption stimulated by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogs EB1089 and KH1060.
Vink-van Wijngaarden T; Birkenhäger JC; Kleinekoort WM; van den Bemd GJ; Pols HA; van Leeuwen JP
Endocrinology; 1995 Feb; 136(2):812-5. PubMed ID: 7835315
[TBL] [Abstract][Full Text] [Related]
16. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
17. Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.
Lykkesfeldt AE; Madsen MW; Briand P
Cancer Res; 1994 Mar; 54(6):1587-95. PubMed ID: 8137264
[TBL] [Abstract][Full Text] [Related]
18. Hybrid structural analogues of 1,25-(OH)2D3 regulate chondrocyte proliferation and proteoglycan production as well as protein kinase C through a nongenomic pathway.
Boyan BD; Posner GH; Greising DM; White MC; Sylvia VL; Dean DD; Schwartz Z
J Cell Biochem; 1997 Sep; 66(4):457-70. PubMed ID: 9282324
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells.
Simboli-Campbell M; Narvaez CJ; van Weelden K; Tenniswood M; Welsh J
Breast Cancer Res Treat; 1997 Jan; 42(1):31-41. PubMed ID: 9116316
[TBL] [Abstract][Full Text] [Related]
20. 1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects.
Wang Q; Lee D; Sysounthone V; Chandraratna RAS ; Christakos S; Korah R; Wieder R
Breast Cancer Res Treat; 2001 May; 67(2):157-68. PubMed ID: 11519864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
